Your browser is no longer supported. Please, upgrade your browser.
Kezar Life Sciences, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own0.70% Shs Outstand50.12M Perf Week-5.04%
Market Cap281.54M Forward P/E- EPS next Y-1.23 Insider Trans0.22% Shs Float31.61M Perf Month-16.05%
Income-41.70M PEG- EPS next Q-0.24 Inst Own52.90% Short Float6.45% Perf Quarter5.81%
Sales- P/S- EPS this Y48.40% Inst Trans0.16% Short Ratio6.78 Perf Half Y-2.75%
Book/sh2.81 P/B2.01 EPS next Y-23.00% ROA-27.10% Target Price- Perf Year21.77%
Cash/sh2.82 P/C2.01 EPS next 5Y- ROE-29.20% 52W Range4.23 - 9.79 Perf YTD8.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.96% Beta-
Dividend %- Quick Ratio22.50 Sales past 5Y- Gross Margin- 52W Low36.64% ATR0.41
Employees47 Current Ratio22.50 Sales Q/Q- Oper. Margin- RSI (14)46.87 Volatility6.30% 7.25%
OptionableYes Debt/Eq0.00 EPS Q/Q56.40% Profit Margin- Rel Volume0.12 Prev Close5.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume300.74K Price5.78
Recom1.60 SMA20-3.13% SMA50-4.79% SMA2006.33% Volume5,350 Change2.30%
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
Apr-19-21 06:45AM  
Apr-10-21 08:30AM  
Feb-25-21 04:01PM  
Feb-16-21 12:53AM  
Feb-10-21 04:01PM  
Jan-07-21 04:02PM  
Dec-18-20 03:13AM  
Dec-15-20 07:52AM  
Dec-14-20 04:01PM  
Nov-12-20 04:05PM  
Nov-05-20 04:01PM  
Oct-23-20 07:26AM  
Oct-19-20 02:25PM  
Oct-15-20 07:00AM  
Sep-18-20 07:30AM  
Sep-17-20 04:01PM  
Sep-10-20 07:00AM  
Aug-11-20 08:59AM  
Aug-05-20 04:01PM  
Aug-03-20 04:01PM  
Jul-29-20 05:17PM  
Jun-23-20 09:16PM  
Jun-16-20 09:36AM  
Jun-12-20 07:01AM  
Jun-09-20 04:15PM  
Jun-08-20 08:48PM  
Jun-03-20 04:02PM  
May-28-20 04:01PM  
May-20-20 04:42PM  
May-11-20 10:35AM  
May-07-20 04:01PM  
May-04-20 04:01PM  
Apr-09-20 06:08PM  
Mar-24-20 11:30AM  
Mar-12-20 04:01PM  
Feb-26-20 04:01PM  
Feb-07-20 08:36AM  
Feb-04-20 05:50PM  
Jan-31-20 08:13AM  
Dec-19-19 07:00AM  
Dec-16-19 07:29AM  
Dec-09-19 04:05PM  
Nov-27-19 04:05PM  
Nov-18-19 11:39AM  
Nov-14-19 09:44AM  
Nov-12-19 07:00AM  
Nov-08-19 04:13PM  
Nov-06-19 04:05PM  
Oct-28-19 04:25PM  
Oct-01-19 04:05PM  
Sep-27-19 02:22PM  
Aug-28-19 04:05PM  
Aug-21-19 01:38PM  
Aug-14-19 03:40PM  
Aug-07-19 04:05PM  
Jul-02-19 09:03PM  
Jun-14-19 08:47AM  
Jun-13-19 04:01PM  
Jun-10-19 04:05PM  
May-29-19 07:38AM  
May-28-19 07:31PM  
May-25-19 10:08AM  
May-20-19 04:53PM  
May-14-19 04:05PM  
May-09-19 08:56PM  
May-07-19 04:05PM  
Apr-03-19 08:00AM  
Mar-28-19 04:05PM  
Mar-26-19 08:00AM  
Mar-06-19 04:05PM  
Mar-05-19 08:00AM  
Mar-04-19 05:00PM  
Dec-20-18 01:05PM  
Dec-05-18 08:00AM  
Nov-26-18 02:03PM  
Nov-08-18 08:00AM  
Nov-07-18 08:00AM  
Aug-29-18 08:00AM  
Aug-09-18 04:05PM  
Jul-17-18 10:00AM  
Jun-29-18 02:39PM  
Jun-28-18 09:07AM  
Jun-25-18 04:05PM  
Jun-21-18 11:41AM  
Jun-20-18 08:05PM  
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fowler John FranklinCEODec 31Option Exercise0.9016,00014,400359,204Jan 04 08:45 PM
Equal Talent Investments Ltd10% OwnerJun 11Buy5.501,454,5457,999,9986,254,545Jun 15 04:10 PM
BERGER FRANKLIN MDirectorJun 11Buy5.50100,000550,000784,003Jun 11 06:29 PM